ELOVL2 and early-onset autosomal dominant Alzheimer disease: Among other potential applications, this epigenetic marker can be used for predicting the development of neurodegenerative diseases, as alterations in the ELOVL2 methylation status have been observed in patients at early stages of Alzheimer’s disease [35].